Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Q1 2025 Management View CEO John Jacobs highlighted the shift in Novavax's corporate strategy over the past year, ...

The stock's rise snapped a three-day losing streak.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates by $322.8 millionand lifting its full-year revenue forecast ...